Global evidence is not local-market ready
HQ sent a 200-slide global deck. Your affiliate needs a 12-slide country brief by Thursday — adapted to local comparators, local guidelines, and local language.
Why this happens
Global decks are built for global audiences
Global medical teams create evidence packages optimized for internal alignment, not local execution. The comparators are international. The guidelines are US- or EU-centric. The format assumes everyone has the same audience.
But affiliates operate in a different reality. A medical director in Turkey competes against a local generic. An MSL in South Korea needs slides adapted to Asian treatment guidelines. A regional market access team needs a value dossier that reflects local reimbursement criteria.
The result: affiliate teams spend weeks manually adapting global materials — or worse, they don’t adapt them at all and present irrelevant evidence to local stakeholders.
“We received a 200-page global dossier. Our payer committee needed a 20-page local brief. Nobody had time to build it.”
— Director, Medical Excellence, CEE, Oncology
Sound familiar?
Typical situations we hear
01
Global deck, local deadline
HQ sends 200 slides. The affiliate needs a 12-slide country brief by Friday — with local comparators, guidelines, and language.
02
Wrong comparator
The global evidence package uses Comparator A. The local HTA body evaluates against Comparator B. The global argument collapses.
03
No local adaptation team
Small affiliates don’t have medical writing capacity. They copy-paste global materials and hope nobody notices the mismatches.
04
8 markets, 8 versions
Each affiliate adapts materials independently. No consistency, no shared template, no central quality control across the region.
What breaks without intervention
The cost of doing nothing
MSLs present irrelevant data
Without local adaptation, field teams use global slides with wrong comparators — undermining credibility with local KOLs and payers.
Launch delays across affiliates
Each market waits 4–8 weeks to manually adapt materials. Launch timelines slip. Competitors move first with localized evidence.
MLR bottleneck multiplies
Every market creates its own version from scratch. Legal-medical review workload multiplies. Approvals stall across the region.
How MAG solves it
From global deck to local-ready output
1
Scoping & gap analysis
We review your global materials and identify what needs adaptation: comparators, guidelines, treatment algorithms, language, and format.
2
Evidence reframing
Our medical experts restructure the evidence around local market reality — correct comparators, local guideline alignment, and market-specific data points.
3
AI-accelerated drafting
Evidence Scanner™ structures the research. Our experts validate every claim, check references, and ensure MLR readiness — cutting drafting time by 50–70%.
4
Multi-market delivery
We deliver localized outputs for multiple markets simultaneously — consistent core story, market-specific adaptation, ready for MLR review.
5
Iteration & updates
One round of revisions included. Post-congress updates and new data integration available on demand — materials stay current.
Services we use to solve this
What you get
Typical deliverables
Country evidence brief
Local comparator dossier
MSL slide deck (localized)
Payer value summary
KOL discussion guide
FAQ document
Rapid post-congress update
Real work. Measurable outcomes.
Related case studies
Country-level evidence adaptation for 8 CEE pharma affiliates — one core brief, 8 local versions
✓ All 8 markets launched within the same quarter with consistent messaging
Read case study →
Global value dossier localized for 5 MENA markets: SGLT2 inhibitor in heart failure
✓ HTA-ready dossiers submitted in all 5 markets within same quarter
Read case study →
Frequently asked
Common questions
Do you work with our existing global materials or start from scratch?
We always start with your existing global evidence package. Our job is to reframe and adapt — not to recreate from scratch.
Can you adapt materials for multiple markets simultaneously?
Yes. We routinely deliver localized outputs for 5–12 markets at once. We create a shared adaptation template, then apply market-specific comparators and guidelines.
How do you handle MLR review requirements across markets?
All our outputs are designed to be MLR-ready from the start. We include source references, annotated claims, and compliance notes.
What role does AI play in the adaptation process?
Evidence Scanner™ accelerates the research and structuring phase — identifying relevant local comparator data, mapping guideline differences, and drafting initial frameworks.
Still have questions about localization?
Book a 20-minute scoping call. We’ll review your situation and suggest the fastest path forward.
Book a scoping call →
Browse all services
Need local-ready
evidence materials?
evidence materials?
Tell us what you’re working on — we respond within 24 hours with a tailored scope and timeline for your market.
AI infrastructure
AI-powered.
Expert-validated.
We built AI workflows into our daily practice — not as a marketing claim, but as the infrastructure that lets our medical experts deliver faster without cutting corners.
Research
Structured PubMed queries with narrative or table outputs
Monitoring
Weekly literature digests by drug, target, or topic
AI-Enhanced EDC
Advisory board transcription + structured AI summary
Fact-Checker
Claim verification against your source documents
AI accelerates. Our experts validate.
Every output goes through expert medical review before it reaches your team. AI handles structure and speed — we handle scientific judgement and MLR readiness.
// Query: ribociclib OS data MONALEESA 2023–24
search("ribociclib overall survival", {
years: [2023, 2024],
output: "structured_table"
})
// 847 records → 23 relevant
Processing 847 records...
Evidence Summary
MONALEESA-2 updated OS (NEJM 2023): median OS 63.9 mo vs 51.4 mo (HR 0.76, 95% CI 0.63–0.93). Benefit maintained across all pre-specified subgroups...